Skip to search formSkip to main contentSkip to account menu

pnu 152243

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

methoxy-morpholinyl-doxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma
Methoxymorpholinyl doxorubicin (PNU 152243) is a morpholinyl analog possessing a methoxymorpholinyl group at the 3′ position of… 
2000
2000
Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent.
Plasma pharmacokinetics, excretion balance and urinary metabolites of methoxymorpholino doxorubicin (MMDX) were investigated in… 
2000
2000
In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Methoxymorpholinyl doxorubicin (MMDX; PNU 152243) is a promising doxorubicin derivative currently undergoing clinical evaluation… 
1999
1999
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
Purpose: The methoxymorpholinyl doxorubicin analogue PNU 152243 was brought into clinical studies because of preclinical… 
1997
1997
Phase IB study of methoxymorpholinodoxorubicin (PNU 152243; FCE 23762) administered in a 3 or 4 weekly schedule
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)